Track 1: Pathophysiology and causes

Osteoporosis is a condition characterized by a decrease in the density of bone, decreasing its strength and resulting in fragile bones. Bones weaken (osteopenia) and over time can become brittle and prone to fracture.

More than 95% of osteoporosis in women and about 80% in men is primary. Most cases occur in postmenopausal women and older men. Gonadal insufficiency is an important factor in both men and women.  Secondary osteoporosis accounts for < 5% of osteoporosis in women and about 20% in men. The causes may also further accelerate bone loss and increase fracture risk in patients with primary osteoporosis. Patients with chronic kidney disease may have several reasons for low bone mass, including secondary hyperparathyroidism, renal osteodystrophy, and adynamic bone.

*Mutations in the LRP5 gene can cause juvenile primary osteoporosis.

Related conferences:-

6^th Annual Surgeons & Orthopedics Conference & Expo September 12-14, 2016 Atlanta, Georgia USA; Global Ortho Congress December 8-10,2016 ( 6 Plenary Forums - 1Event) Philadelphia, USA; 2nd International conference on Osteoporosis & Musculoskeletal Disorders,May 22-24, 2017 Mexico, USA; International Conference on Metabolic Syndromes, October 17-18, 2016 Rome, Italy; WCO-IOF-ESCEO Florence 2017 Fortezza da basso, Florence, Italy, march 23-26,  2017; ECTS 2017 - 44th European Calcified Tissue Society Congress, Salzburg, Austria 13 to 16 May 2017;  Bone Research Society Annual Meeting, Bristol, UK,25-27 June 2017; 13th International Conference on Osteogenesis Imperfecta, Oslo, Norway, August 27th – 30th 2017.

Track 2: Clinical diagnosis and tools

Dual-energy X-ray absorptiometry scan (DXA, formerly known as DEXA) be used for the diagnosis of osteoporosis. DXA typically measures bone density in the hip, the spine, and the forearm and exposes patients to very little radiation.  Radiography is useful, both by itself and in conjunction with CT or MRI, for detecting complications of osteopenia (reduced bone mass; pre-osteoporosis). The main radiographic features of generalized osteoporosis are cortical thinning and increased radiolucency.  Chemical biomarkers are a useful tool in detecting bone degradation. Quantitative computed tomography reports precise volumetric mineral density in mg/cm3 Portable and relatively inexpensive ultrasound machines have been developed, which are designed to look at bone structure and strength, usually of the heel bone (calcaneus), wrist or finger. Blood tests include those that measure levels of calcium, thyroid-stimulating hormone, parathyroid hormone, the enzyme alkaline phosphatase, and vitamin D, as well as kidney and liver functions. Calcium and cortisol may be measured in the urine.

Related conferences:-

6th Annual Surgeons & Orthopedics Conference & Expo September 12-14, 2016 Atlanta, Georgia USA ; Global Ortho Congress December 8-10,2016 ( 6 Plenary Forums - 1Event) Philadelphia, USA; International Conference on Medical Imaging & Diagnosis, October 20-21, 2016 Chicago, Illinois, USA; 2nd International conference on Osteoporosis & Musculoskeletal Disorders,May 22-24, 2017 Mexico, USA; 8^th annual Next Generation Dx Summit, Washington DC,USA, august 23-26,2016; The Diagnostic Conference September 29-30, 2016, San Francisco, USA; WCO-IOF-ESCEO Florence 2017 Fortezza da basso, Florence, Italy march 23-26,  2017; International Skeletal Society 43rd Annual Meeting And Musculoskeletal Imaging Course 2016 September  7- 9, 2016,PARIS , FRANCE

Track 3: Present scenario and risk factor

Worldwide, osteoporosis causes more than 8.9 million fractures annually, resulting in an osteoporotic fracture every 3 seconds. Due to its prevalence worldwide, osteoporosis is considered a serious public health concern. Currently it is estimated that over 200 million people worldwide suffer from this disease. Approximately 30% of all postmenopausal women have osteoporosis in the United States and in Europe. At least 40% of these women and 15-30% of men will sustain one or more fragility fractures in their remaining lifetime. Ageing of populations worldwide will be responsible for a major increase in the incidence of osteoporosis in postmenopausal women. 2.3-fold increased risk of future hip fracture and a 1.4-fold increase in risk of distal forearm fracture seen. The number of new fractures in 2010 in the EU was estimated at 3.5 million,. Canada: Osteoporosis affects approximately 1.4 million Canadians, mainly postmenopausal women and the elderly (142). Osteoporosis affects 1 in 4 women and more than 1 in 8 men over the age of 50 years, with 1 in 4 men and women having evidence of a vertebral fracture. USA: The 44 million people with either osteoporosis or low bone mass represent 55 percent of the people aged 50 and older in the United States.

Related conferences:-

4th International Conference on Epidemiology and Public Health, October 03-05, 2016 London, United Kingdom; 2nd World Congress on Public Health and Nutrition ,March 22-24, 2017 Rome, Italy; 6th Annual Surgeons & Orthopedics Conference & Expo September 12-14, 2016 Atlanta, Georgia USA; Global Ortho Congress December 8-10,2016 ( 6 Plenary Forums - 1Event) Philadelphia, USA; 2nd International conference on Osteoporosis & Musculoskeletal Disorders,May 22-24, 2017 Mexico, USA; WCO-IOF-ESCEO Florence 2017 Fortezza da basso, Florence, Italy march 23-26,  2017; ECTS 2017 - 44th European Calcified Tissue Society Congress, Salzburg, Austria, 13 to 16 May 2017; 13th International Conference on Osteogenesis  Imperfecta , Oslo, Norway, August 27th – 30th 2017;  Bone Research Society Annual Meeting Bristol, UK,25-27 June 2017; ICEID 2017 : 19th International Conference on Epidemiology and Infectious Diseases, Boston, USA, April 24 - 25, 2017.

Track 4: Symptoms , complications and prevention

A person is often not aware that he or she has osteoporosis until a fracture occurs. But there are occasionally symptoms of the disorder. They could include: Backache, a gradual loss of height and an accompanying stooped posture, fractures of the spine, wrist, or hip

Bone fractures, particularly in the spine or hip, are the most serious complication of osteoporosis. Hip fractures often are caused by a fall and can result in disability and even an increased risk of death within the first year after the injury. In some cases, spinal fractures are increased risk of mortality. Osteoporosis may also lead to blood clotting and pulmonary embolism. Preventing osteoporosis by smoking cessation and moderation of alcohol intake are commonly recommended. Reviewing the drugs constantly is required.

Related conferences:

6th Annual Surgeons & Orthopedics Conference & Expo September 12-14, 2016 Atlanta, Georgia USA; Global Ortho Congress December 8-10,2016 ( 6 Plenary Forums - 1Event) Philadelphia, USA; 2nd International conference on Osteoporosis & Musculoskeletal Disorders,May 22-24, 2017 Mexico, USA; International Conference on Metabolic Syndromes, October 17-18, 2016 Rome, Italy; WCO-IOF-ESCEO Florence 2017, Fortezza da basso, Florence, Italy, march 23-26, 2017; ECTS 2017 - 44th European Calcified Tissue Society Congress, Salzburg, Austria            13 to 16 May 2017;  Bone Research Society Annual Meeting, Bristol, UK,25-27 June 2017; 13th International Conference on Osteogenesis Imperfecta, Oslo, Norway, August 27th – 30th 2017.

Track 5: Endocrinology in osteoporosis and secondary causes

Hormonal factors strongly determine the rate of bone resorption; lack of estrogen (e.g. as a result of menopause) increases bone resorption, as well as decreasing the deposition of new bone that normally takes place in weight-bearing bones. The amount of estrogen needed to suppress this process is lower than that normally needed to stimulate the uterus and breast gland. calcium metabolism plays a significant role in bone turnover, and deficiency of calcium and vitamin D leads to impaired bone deposition; in addition, the parathyroid glands react to low calcium levels by secreting parathyroid hormone (parathormone, PTH), which increases bone resorption to ensure sufficient calcium in the blood.

Studies have found an increased risk of bone loss and fracture in individuals with rheumatoid arthritis. To begin with, the glucocorticoid medications often prescribed for the treatment of rheumatoid arthritis can trigger significant bone loss.The unique aspects of gastrointestinal diseases associated with osteoporosis include early onset of disease (and, therefore, prolonged exposure to risk factors for developing osteoporosis, particularly with inflammatory bowel disease and celiac disease), malabsorption, and maldigestion of nutrients

Related conferences:-

International Conference on Metabolic Syndromes, October 17-18, 2016 Rome, Italy; 2^nd International Conference on Thyroid Disorders and Treatment, April 10-12, 2017 Munich, Bavaria, Germany;  6^th International Conference on Diabetes and Endocrinology ,December 05-07, 2016 Dallas, USA; 2nd International conference on Osteoporosis & Musculoskeletal Disorders,May 22-24, 2017 Mexico, USA; 8th International Conference of Orthopedic Surgeons and Rheumatology, March 14-15, 2017, Madrid, Spain; BRAZILIAN CONGRESS OF ENDOCRINOLOGY AND METABOLISM 2016 SEPTEMBER 20- 24, 2016.BAHIA , BRAZIL; 13th International Conference on Osteogenesis Imperfecta ,Oslo, Norway, August 27th – 30th 2017;  Bone Research Society Annual Meeting, Bristol, UK      25-27 June 2017; WCO-IOF-ESCEO Florence 2017,Fortezza da basso, Florence, Italy, march 23-26,  2017                       

Track 6: Treatment and supportive approaches

Teriparatide (a recombinant parathyroid hormone ) has been shown to be effective in treatment of women with postmenopausal osteoporosis. SERMs were developed to reap the benefits of estrogen while avoiding the hormone's potential side effects. Raloxifene, a so-called ''designer'' estrogen, can act like estrogen on bone -- protecting its density -- but as an anti-estrogen on the lining of the uterus. Some evidence also indicates strontium ranelate is effective in decreasing the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis Hormone replacement therapy, while effective for osteoporosis, is only recommended in women who also have menopausal symptoms.                                               Kyphoplasty is a minimally invasive surgical procedure used for treating fractures caused by osteoporosis. Vertebral augmentation is a surgical procedure used to treat a compression fracture of the spine similar to other procedures like kyphoplasty or vertebroplasty.            An orthosis is an externally applied device used to modify the structural and functional characteristics of the neuromuscular and skeletal system.

Calcium and vitamin D supplements may be given for effective recovery.

Related conferences:-

8th International Conference of Orthopedic Surgeons and Rheumatology, March 14-15, 2017, Madrid, Spain; International Conference on Arthroplasty, July 17-19, 2017 Munich, Germany; 2nd International conference on Osteoporosis & Musculoskeletal Disorders,May 22-24, 2017 Mexico, USA; 6th Annual Surgeons & Orthopedics Conference & Expo September 12-14, 2016 Atlanta, Georgia USA; Global Physicians and Surgeons Congress November 17-19, 2016 Atlanta, USA; 13th International Conference on Osteogenesis Imperfecta ,Oslo, Norway, August 27th – 30th 2017; BRITISH ORTHOPAEDIC RESEARCH SOCIETY 2016, September  5- 7, 2016,GLASGOW , UNITED KINGDOM; ISPO World Congress 2017,Cape Town, South Africa ,May 8-11,2017; ASBMR 2017 Annual Meeting,  Denver, Colorado, USA, September 8 – 11, 2017.                      

 

Track 7: Pharmaceutical and prosthetics market

Global Osteoporosis Market is estimated to be USD 7.3 billion in 2010 and expected to reach USD 11.4 billion in 2015 at a CAGR of 9.2% over the period 2010 to 2015. Bisphosphonate segment accounted for the largest share at 62.0% of weight management market in 2010. China Osteoporosis market was worth USD 2.5 billion in 2015. Osteoporosis Market may Cross $40 Billion by 2019 according to Global Osteoporosis Market, Patients, Companies & Forecast (2015)

North America is the dominant market of orthotic devices and will continue to lead the market in future. The major trend driving the market in this region is increase in incidences of chronic diseases that includes diabetes, arthritis and cancer. Europe followed by APAC are the other leading region of the market. The major driving factor for growth of this market in Europe is rapidly aging population as well as availability of a wide patient pool requiring urgent orthotic support and attention. APAC has population account for over half of world’s aged population. Thus, this region is the fastest emerging market.

Related conferences:-

11^th World Drug Delivery Summit, October 16-18, 2017 New York, USA; International Conference on Pharma Marketing, November 10-11, 2016 Alicante, Spain; International Conference on Medical Devices ,September 21-22, 2015 Orlando, USA; 6th Annual Surgeons & Orthopedics Conference & Expo September 12-14, 2016 Atlanta, Georgia USA, 2nd International Conference and Expo on Biomechanics and Implant Design November 07-09, 2016, Las Vegas, Nevada, USA; ASBMR 2017 Annual Meeting, Denver, Colorado, USA,September 8 – 11, 2017, 43rd Academy Annual Meeting and Scientific Symposium, march 1-4, Chicago, USA; 2017,GSOP Meeting,March 23-25,2017,Wyndham,Atlanta, USA; The ISPO World Congress 2017,Cape Town, South Africa, May 8-11,2017

Track 8: Osteoporosis research and development

Various research works on osteoporosis in understanding the complete pathophysiology are in progress worldwide. New and efficient treatment ways using different approaches are in development. New medicines and treatment methods are being researched globally. Most important research is based on bone remodeling and genetics related to bone formation.

·                     Global Ortho Congress December 8-10,2016 ( 6 Plenary Forums - 1Event) Philadelphia, USA; 6th Annual Surgeons & Orthopedics Conference & Expo September 12-14, 2016 Atlanta, Georgia USA, 2nd International conference on Osteoporosis & Musculoskeletal Disorders,May 22-24, 2017 Mexico, USA;  International Conference on Arthroplasty, July 17-19, 2017 Munich, Germany; World Congress on Human Genetics, November 07- 08, 2016 Barcelona, Spain; WCO-IOF-ESCEO Florence 2017, Fortezza da basso, Florence, Italy , march 23-26,  2017, Osteoporosis Conference 2016,7 - 9 November 2016, Birmingham; ASBMR 2017 Annual Meeting, Denver, Colorado, USA, September 8 – 11, 2017; ECTS 2017 - 44th European Calcified Tissue Society Congress, Salzburg, Austria            13 to 16 May 2017.

Track 9: Alternative treatment

Due to many side effects and complications of conventional methods of treating osteoporosis a definitive need for alternative approaches are needed. Bone morphogenetic proteins (BMPs) are a group of growth factors also known as cytokines and as metabologens.[1] Originally discovered by their ability to induce the formation of bone and cartilage, BMPs are now considered to constitute a group of pivotal morphogenetic signals, orchestrating tissue architecture throughout the body. There's calcium and vitamin D, both key to bone health. Exercise is another critical part of strengthening bone mass and recommend eating plenty of calcium-rich foods, such as nonfat milk, low-fat yogurt, broccoli, cauliflower, salmon, tofu, and leafy green vegetables. Acupuncture and Tai Chi Used for Osteoporosis. While more scientific research is needed on the subject, some herbs and supplements are believed to reduce or potentially stop bone loss caused by osteoporosis. There are numerous benefits to using physiotherapy as a method for treating patients with osteoporosis.

Related conferences:-

5^th International Conference and Exhibition on Natural & Alternative Medicine, September 05-07, 2016 Beijing, China; International conference on Ayurveda, Homeopathy and Chinese Medicine, May 18-19, 2017 Munich, Germany; Annual Meeting on Naturopathic Physicians & Acupuncturists, July 24-26, 2017 Melbourne, Australia; World Physiotherapists & Physicians Summit July 24-26, 2017 Melbourne, Australia; 3^rd International Conference and Expo on Physiotherapy, October 13-15, 2016 Kuala Lumpur, Malaysia; Osteoporosis Conference 2016,7 - 9 November 2016, Birmingham; World confederation for physical therapy congress 2017,2-4 of July 2017.Cape town, South Africa; ICP 2017 : 19th International Conference on Physiotherapy, January 19-20,  London United Kingdom; world congress Integrative Medicine & Health 2017 ,10th ECIM & 12th ICCMR Congress, May 3-5th 2017, Berlin, Germany.

Track 10: Advancements in surgeries and diagnostic tools

In a kyphoplasty, an inflatable balloon is placed into the vertebral body to restore the vertebral height and correction of kyphosis. After deflation, the cavity formed after withdrawal of the balloon is filled by injection of bone cement. While vertebroplasty and kyphoplasty have been widely accepted and applied. Vesselplasty is a surgical alternative in the treatment of vertebral compression fractures (VCFs). It is an image-guided procedure that requires conscious sedations and either general or local anesthesia. Vesselplasty is a latest minimally invasive procedure that increases mobility and reduces the pain of patients’ with vertebral compression fractures by restoring the height of compressed vertebrae.

A major disadvantage of DXA is that currently there is a lack of standardization in bone and soft tissue measurements. There are large discrepancies in measurements obtained on instruments from the three major manufacturers of DXA machines.

Related conferences:-

·                     8th International Conference of Orthopedic Surgeons and Rheumatology, March 14-15, 2017, Madrid, Spain; International Conference on Arthroplasty, July 17-19, 2017 Munich, Germany; 2nd International conference on Osteoporosis & Musculoskeletal Disorders,May 22-24, 2017 Mexico, USA; 6th Annual Surgeons & Orthopedics Conference & Expo September 12-14, 2016 Atlanta, Georgia USA; Global Physicians and Surgeons Congress November 17-19, 2016 Atlanta, USA; 13th International Conference on Osteogenesis Imperfecta ,Oslo, Norway, August 27th – 30th 2017; British Orthopaedic Research Society 2016, September  5- 7, 2016,Glasgow , United Kingdom; ISPO World Congress 2017,Cape Town, South Africa ,May 8-11,2017; ASBMR 2017 Annual Meeting,  Denver, Colorado, USA, September 8 – 11, 2017, Osteoporosis Conference 2016,7 - 9 November 2016, Birmingham.

 

About the conference:

 International Conference on Osteoporosis -2017 welcomes attendees, presenters, and exhibitors from all over the world to Madrid, Spain. We are glad to invite you all to register and attend the “International Conference on Osteoporosis” which is going to be held during September 28-29, 2017 at Madrid, Spain.

The organizing committee of International Conference on Osteoporosis -2017   is preparing for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the International Conference on Osteoporosis -2017, where you can have a present outlook of osteoporosis and its market.

Importance and scope:

Medical doctors, patients and health care providers consider the prevention of orthopedic diseases as an essential tool to improve the general health status of the population. Worldwide, osteoporosis causes more than 8.9 million fractures annually, resulting in an osteoporotic fracture every 3 seconds Osteoporosis is estimated to affect 200 million women worldwide .Increase in osteoporosis cases results in a decline in economy with respect to health. Hence it is necessary to start a global initiative for awareness, prevention and effective treatment of osteoporosis.

International Conference on Osteoporosis -2017 aims at gathering physicians,  rheumatologists, young researchers, students, physiatrists, orthopedists, and geriatricians at global platform to present their respective views and research regarding osteoporosis and share knowledge about osteoporosis for betterment of both academia and business.

Why Spain?

Bone mineral density measurement is underutilized in majority of European countries. Reasons include limited availability of densitometers, restrictions in personnel permitted to perform scans, low awareness of usefulness of BMD testing, limited or nonexistent reimbursement. Spain: In 2010 approximately 204,000 new fragility fractures; number of people aged 50+ with osteoporosis, approximately 2,450,000; economic burden of new and prior fractures € 2,842 million each year; by 2025 burden will increase by 30 % to € 3.68 billion .

In Spain there was a 54% increase in new cases of hip fracture within a 14-year period (1998-2002). This increase occurred mainly in women (64%) compared to men (19%) .Spain: 13% of patients who have suffered a fracture die after 3 months and this figure rises to 38% after 24 months. Furthermore, after experiencing a vertebral fracture, 45% of patients suffer from functional damage and 50% are afflicted by partial or total disability in Spain.

Long-term disability costs were estimated around € 51,786 with the simulated number of individuals with prior fractures that had been transferred to nursing homes due to the fracture.  Patients on treatment made an annual physician visit costing € 109 and a DXA scan costing € 79 every second year to monitor treatment. The cost of osteoporosis in 2010 was estimated at € 2,842 million. First year costs, subsequent year costs and pharmacological fracture prevention costs amounted to € 1,372 million, € 1,055 million and € 414 respectively.

 

 

List of major companies producing drugs for osteoporosis treatment:-

• ·         Merck
• ·         Novartis
• ·         Sunofi
• ·         Eli lilly and company
• ·        Amgen

 

Osteoporosis- present and future scenario:

In the year 2000 there were an estimated 9.0 million osteoporotic fractures of which 1.6 million were at the hip, 1.7 million at the forearm and 1.4 million were clinical vertebral fractures. The greatest number of osteoporotic fractures occurred in Europe (34.8%).present survey reveals Osteoporosis is estimated to affect 200 million women worldwide - approximately one-tenth of women aged 60, one-fifth of women aged 70, two-fifths of women aged 80 and two-thirds of women aged 90. About 22 million women and 5.5 million men in the European Union had osteoporosis in 2010. In the United States in 2010 about 8 million women and one to 2 million men had osteoporosis. This places a large economic burden on the healthcare system due to costs of treatment, long-term disability, and loss of productivity in the working population. The EU spends 37 billion euros per year in healthcare costs related to osteoporosis, and the USA spends an estimated 19 billion USD annually for related healthcare costs. The prevalence of osteoporosis is continuing to escalate with the increasingly elderly population. The major complication of osteoporosis is an increase in fragility fractures leading to morbidity, mortality, and decreased quality of life. In the European Union, in 2000, the number of osteoporotic fractures was estimated at 3.79 million. A baseline fracture is a very strong predictor of further fractures with 20% of patients experiencing a second fracture within the first year. Osteoporosis Drugs Market to Reach US$8.9 billion in 2020 owing to High Incidence of Osteoporosis. The costs to health care services are already considerable and, on current trends, are predicted to double by 2050.